BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 29762238)

  • 21. Initial Institutional Experience with 18F-Fluciclovine PET-CT in Biochemical Recurrence of Prostate Cancer.
    Farkas AB; Green ED; Thaggard AL; Vijayakumar V; Henegan JC; Lirette ST; Nittala MR; Vijayakumar S
    South Med J; 2021 Nov; 114(11):703-707. PubMed ID: 34729614
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of
    Kim SJ; Lee SW
    Clin Radiol; 2019 Nov; 74(11):886-892. PubMed ID: 31358294
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Impact of Positron Emission Tomography with 18F-Fluciclovine on the Treatment of Biochemical Recurrence of Prostate Cancer: Results from the LOCATE Trial.
    Andriole GL; Kostakoglu L; Chau A; Duan F; Mahmood U; Mankoff DA; Schuster DM; Siegel BA;
    J Urol; 2019 Feb; 201(2):322-331. PubMed ID: 30179618
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Effect of Including Bone in Dixon-Based Attenuation Correction for
    Elschot M; Selnæs KM; Johansen H; Krüger-Stokke B; Bertilsson H; Bathen TF
    J Nucl Med; 2018 Dec; 59(12):1913-1917. PubMed ID: 29728516
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A review discussing fluciclovine (
    Zanoni L; Bossert I; Matti A; Schiavina R; Pultrone C; Fanti S; Nanni C
    Future Oncol; 2018 May; 14(11):1101-1115. PubMed ID: 29359581
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of hormonal therapy on
    Bulbul JE; Hashem A; Grybowski D; Joyce C; Rashad E; Gabriel MS; Wagner RH; Savir-Baruch B
    Urol Oncol; 2022 Aug; 40(8):379.e9-379.e16. PubMed ID: 35738974
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [
    Alemozaffar M; Akintayo AA; Abiodun-Ojo OA; Patil D; Saeed F; Huang Y; Osunkoya AO; Goodman MM; Sanda M; Schuster DM
    J Urol; 2020 Oct; 204(4):734-740. PubMed ID: 32347780
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fluorine-18-Labeled Fluciclovine PET/CT in Primary and Biochemical Recurrent Prostate Cancer Management.
    Marcus C; Butler P; Bagrodia A; Cole S; Subramaniam RM
    AJR Am J Roentgenol; 2020 Aug; 215(2):267-276. PubMed ID: 32551903
    [No Abstract]   [Full Text] [Related]  

  • 29. PET Tracer
    Oka S; Kanagawa M; Doi Y; Schuster DM; Goodman MM; Yoshimura H
    Theranostics; 2017; 7(7):2048-2064. PubMed ID: 28656060
    [No Abstract]   [Full Text] [Related]  

  • 30. Initial Results of a Prospective Clinical Trial of 18F-Fluciclovine PET/CT in Newly Diagnosed Invasive Ductal and Invasive Lobular Breast Cancers.
    Ulaner GA; Goldman DA; Gönen M; Pham H; Castillo R; Lyashchenko SK; Lewis JS; Dang C
    J Nucl Med; 2016 Sep; 57(9):1350-6. PubMed ID: 26940766
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Utility of
    Wang Y; Chow DZ; Ebert E; Tajmir S; Scott JA; Palmer EL
    AJR Am J Roentgenol; 2020 Oct; 215(4):997-1001. PubMed ID: 32569513
    [No Abstract]   [Full Text] [Related]  

  • 32. Fluorine-18-Labeled Fluciclovine PET/CT in Clinical Practice: Factors Affecting the Rate of Detection of Recurrent Prostate Cancer.
    Savir-Baruch B; Lovrec P; Solanki AA; Adams WH; Yonover PM; Gupta G; Schuster DM
    AJR Am J Roentgenol; 2019 Oct; 213(4):851-858. PubMed ID: 31216198
    [No Abstract]   [Full Text] [Related]  

  • 33. 18F-Fluciclovine PET/CT Detection of Recurrent Prostate Carcinoma in Patients With Serum PSA ≤ 1 ng/mL After Definitive Primary Treatment.
    England JR; Paluch J; Ballas LK; Jadvar H
    Clin Nucl Med; 2019 Mar; 44(3):e128-e132. PubMed ID: 30589673
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is There Any Role for 18F-Fluciclovine PET/CT in the Presence of Undetectable PSA in Prostate Cancer Patients After Definitive Treatment?
    Teyateeti A; Teyateeti A; Macapinlac HA; Lu Y
    Clin Nucl Med; 2020 Sep; 45(9):672-678. PubMed ID: 32604105
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of
    Jani AB; Schreibmann E; Rossi PJ; Shelton J; Godette K; Nieh P; Master VA; Kucuk O; Goodman M; Halkar R; Cooper S; Chen Z; Schuster DM
    J Nucl Med; 2017 Mar; 58(3):412-418. PubMed ID: 27609792
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Extraprostatic Uptake of
    Robertson MS; Sakellis CG; Hyun H; Jacene HA
    AJR Am J Roentgenol; 2020 Mar; 214(3):641-648. PubMed ID: 31939697
    [No Abstract]   [Full Text] [Related]  

  • 37. Impact of
    Andriole GL; Scarsbrook AF; Savir-Baruch B;
    Urol Oncol; 2023 Jun; 41(6):293.e1-293.e7. PubMed ID: 37121865
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Detection of Additional Primary Neoplasms on
    Parihar AS; Schmidt LR; Dehdashti F; Wahl RL
    J Nucl Med; 2022 May; 63(5):713-719. PubMed ID: 34413144
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    Rais-Bahrami S; Efstathiou JA; Turnbull CM; Camper SB; Kenwright A; Schuster DM; Scarsbrook AF
    Prostate Cancer Prostatic Dis; 2021 Dec; 24(4):997-1006. PubMed ID: 34012062
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diagnostic accuracy of 18F-fluciclovine PET/CT in primary lymph node staging of prostate cancer.
    Hoekstra RJ; Beulens A; Vrijhof EHJEJ; Wyndaele DNJ; Roef M; Brouwer LJM; Somford DM; Sedelaar M; van Basten JA
    Nucl Med Commun; 2021 May; 42(5):476-481. PubMed ID: 33323869
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.